{"id":"fluciclovine-pet-ct","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Radiation exposure (expected from PET tracer)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluciclovine (18F-FACBC) is taken up preferentially by cancer cells due to their elevated amino acid transport and metabolism compared to normal tissue. The fluorine-18 radiolabel allows positron emission tomography (PET) imaging to visualize areas of increased uptake, which correlates with malignant disease. This mechanism enables improved detection and localization of tumors for diagnostic and staging purposes.","oneSentence":"Fluciclovine is a fluorine-18 labeled amino acid analog that accumulates in cancer cells with high amino acid metabolism, enabling PET/CT imaging detection of malignant lesions.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:46:37.758Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"PET imaging of suspected prostate cancer recurrence in men with elevated PSA"},{"name":"Detection and localization of various malignancies with high amino acid metabolism"}]},"trialDetails":[{"nctId":"NCT06064097","phase":"PHASE2","title":"A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-25","conditions":"Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8","enrollment":50},{"nctId":"NCT04423211","phase":"PHASE3","title":"Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-10-08","conditions":"Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma","enrollment":804},{"nctId":"NCT06103838","phase":"PHASE2","title":"18F-Fluciclovine PET/CT in Multiple Myeloma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-03-25","conditions":"Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Relapsed and/or Refractory Multiple Myeloma (RRMM)","enrollment":60},{"nctId":"NCT04689048","phase":"PHASE1","title":"Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery","status":"RECRUITING","sponsor":"Baptist Health South Florida","startDate":"2022-04-04","conditions":"Brain Metastases, Adult, Brain Metastases, Brain Cancer","enrollment":20},{"nctId":"NCT04018053","phase":"EARLY_PHASE1","title":"18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2020-02-26","conditions":"Bladder Cancer, Urothelial Carcinoma","enrollment":16},{"nctId":"NCT05053152","phase":"PHASE2","title":"Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2022-04-20","conditions":"Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Ductal Adenocarcinoma","enrollment":194},{"nctId":"NCT04175431","phase":"PHASE2","title":"Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study","status":"RECRUITING","sponsor":"University of Washington","startDate":"2020-09-30","conditions":"Prostate Adenocarcinoma","enrollment":100},{"nctId":"NCT05554302","phase":"PHASE2","title":"Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis","status":"RECRUITING","sponsor":"Baptist Health South Florida","startDate":"2023-01-10","conditions":"Brain Metastases, Brain Cancer","enrollment":20},{"nctId":"NCT05722925","phase":"PHASE4","title":"Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2023-10-04","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT06062745","phase":"PHASE1","title":"Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2024-02-01","conditions":"Advanced Prostate Cancer, Metastatic Prostate Cancer, Metastatic Prostate Neuroendocrine Carcinoma","enrollment":30},{"nctId":"NCT06015295","phase":"NA","title":"A Pilot Study to Assess the Clinical Utility of 18F-Fluciclovine (Axumin) PET-CT for Detecting True-versus Pseudo-Progression of Brain Metastases on Immunotherapy","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-11-07","conditions":"Brain Metastases","enrollment":20},{"nctId":"NCT06055790","phase":"PHASE2","title":"Feasibility of 18F-Fluciclovine PET/CT to Identify Brain Metastasis","status":"RECRUITING","sponsor":"University of Arizona","startDate":"2024-09-10","conditions":"Brain Metastases","enrollment":20},{"nctId":"NCT03426865","phase":"","title":"Role of Axumin PET Scan in Germ Cell Tumor","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2018-03-01","conditions":"Testis Cancer, Germ Cell Tumor, Testicular Cancer","enrollment":10},{"nctId":"NCT06866782","phase":"","title":"European Registry of Next Generation Imaging in Advanced Prostate Cancer","status":"RECRUITING","sponsor":"Fundacio Puigvert","startDate":"2024-09-17","conditions":"Prostate Cancer, Advanced Prostate Cancer, Metastatic Prostate Cancer (mPC)","enrollment":600},{"nctId":"NCT06859203","phase":"","title":"A Prospective, Bicentric Evaluation of Fluciclovine PET-imaging in Patients with Prior Negative or Inconclusive PSMA-ligand PET","status":"RECRUITING","sponsor":"Technical University of Munich","startDate":"2025-03","conditions":"Biochemical Recurrence of Malignant Neoplasm of Prostate","enrollment":94},{"nctId":"NCT04750473","phase":"PHASE1","title":"Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer","status":"COMPLETED","sponsor":"Emory University","startDate":"2021-07-16","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Lobular Carcinoma, Metastatic Breast Lobular Carcinoma","enrollment":20},{"nctId":"NCT04134208","phase":"PHASE4","title":"An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-09-19","conditions":"Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":2},{"nctId":"NCT03276676","phase":"PHASE1, PHASE2","title":"[18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors","status":"TERMINATED","sponsor":"University of Utah","startDate":"2018-09-24","conditions":"Brain Tumor","enrollment":10},{"nctId":"NCT05313191","phase":"NA","title":"Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors","status":"RECRUITING","sponsor":"The New York Proton Center","startDate":"2022-01-24","conditions":"CNS Cancer, Head and Neck Cancer, GI Cancer","enrollment":1800},{"nctId":"NCT03707184","phase":"PHASE2","title":"Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone","status":"COMPLETED","sponsor":"University of Utah","startDate":"2018-10-02","conditions":"Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer","enrollment":17},{"nctId":"NCT06706921","phase":"PHASE4","title":"18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer","status":"RECRUITING","sponsor":"VA Greater Los Angeles Healthcare System","startDate":"2024-12-15","conditions":"Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Metastatic Prostate Cancer","enrollment":15},{"nctId":"NCT03926507","phase":"NA","title":"F18 Fluciclovine PET/CT in Assessing Tumor Volume and Radiation Therapy Response in Patients With Glioblastoma Undergoing Surgery","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-04-30","conditions":"Glioblastoma","enrollment":12},{"nctId":"NCT04852523","phase":"EARLY_PHASE1","title":"18F-Fluciclovine PET/CT in the Assessment of Pancreatic Transplants","status":"COMPLETED","sponsor":"University of Utah","startDate":"2021-09-16","conditions":"Pancreatitis, Graft, Pancreatic Transplant Post-Transplant Dysfunction Rejection","enrollment":4},{"nctId":"NCT03925675","phase":"PHASE2","title":"18F-Fluciclovine PET and Multiparametric MR Imaging","status":"WITHDRAWN","sponsor":"Loma Linda University","startDate":"2020-08-24","conditions":"Brain Tumor, Recurrent, Adult","enrollment":""},{"nctId":"NCT03762759","phase":"PHASE2","title":"Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2019-05-10","conditions":"Prostate Adenocarcinoma","enrollment":140},{"nctId":"NCT03868020","phase":"EARLY_PHASE1","title":"Fluciclovine F18 PET/CT in Identifying the Origin of Head and Neck Squamous Cell Carcinoma in Patients With Metastatic Cervical Nodal Disease","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-04-24","conditions":"Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma in Cervical Lymph Node","enrollment":16},{"nctId":"NCT04234399","phase":"","title":"Determination of the Diagnostic Detection Rate of Axumin (Fluciclovine) Digital PET/CT, Post-prostatectomy","status":"TERMINATED","sponsor":"University of Vermont","startDate":"2020-03-01","conditions":"Prostatic Neoplasm","enrollment":22},{"nctId":"NCT01666808","phase":"PHASE2, PHASE3","title":"FACBC Outcomes for Post Prostatectomy","status":"COMPLETED","sponsor":"Emory University","startDate":"2012-09","conditions":"Prostate Cancer","enrollment":165},{"nctId":"NCT03527199","phase":"","title":"Prostate Cancer Patients With Biochemical Recurrence","status":"COMPLETED","sponsor":"Medhat Osman","startDate":"2018-12-18","conditions":"Patients With Prostate Cancer","enrollment":65},{"nctId":"NCT03496844","phase":"NA","title":"Fluciclovine-PET/CT for Bone Metastases From Prostate Adenocarcinoma","status":"COMPLETED","sponsor":"University of Arizona","startDate":"2018-04-15","conditions":"Prostate Adenocarcinoma","enrollment":15},{"nctId":"NCT03373006","phase":"PHASE2","title":"A Phase II Study to Evaluate Axumin PET/CT for Risk Stratification for Prostate Cancer","status":"COMPLETED","sponsor":"HALO Diagnostics","startDate":"2018-02-27","conditions":"Prostate Cancer","enrollment":20},{"nctId":"NCT04765423","phase":"NA","title":"Fluciclovine (Axumin) PET/CT vs. NaF PET/CT in Prostate Cancer Osseous Metastatic Disease","status":"WITHDRAWN","sponsor":"Case Comprehensive Cancer Center","startDate":"2021-03-25","conditions":"Malignant Neoplasm of Prostate","enrollment":""},{"nctId":"NCT03990285","phase":"PHASE1","title":"[18F]Fluciclovine in Post-treatment Glioblastoma ( Axumin )","status":"COMPLETED","sponsor":"Ali Nabavizadeh","startDate":"2019-06-12","conditions":"Glioma Glioblastoma Multiforme","enrollment":30},{"nctId":"NCT03930173","phase":"EARLY_PHASE1","title":"18F-Fluciclovine PET to Distinguish Tumor Progression From Radiation Necrosis","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2019-07-02","conditions":"Secondary Malignant Neoplasm of Brain and Cerebral Meninges","enrollment":18},{"nctId":"NCT03081884","phase":"PHASE2","title":"Validation of FACBC for Detection of Metastasis Among High-risk Prostate Cancer Patients With Presumed Localized Disease","status":"COMPLETED","sponsor":"Emory University","startDate":"2017-03-01","conditions":"Cancer","enrollment":61},{"nctId":"NCT03423082","phase":"PHASE4","title":"Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer.","status":"TERMINATED","sponsor":"Nghi Nguyen","startDate":"2018-12-11","conditions":"Cervical Cancer, Uterine Cancer","enrollment":1},{"nctId":"NCT03515577","phase":"PHASE2","title":"Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After Surgery","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-04-12","conditions":"Recurrent Prostate Carcinoma","enrollment":50},{"nctId":"NCT03349463","phase":"PHASE4","title":"Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers.","status":"UNKNOWN","sponsor":"Bital Savir-Baruch","startDate":"2018-11-14","conditions":"Cervical Cancer, Endometrial Cancer, Ovarian Epithelial Cancer","enrollment":30},{"nctId":"NCT04239742","phase":"NA","title":"F18-PSMA-1007 PET for Early Biochemical Recurrence of Prostate Cancer","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2020-01-02","conditions":"Prostate Cancer Recurrent","enrollment":50},{"nctId":"NCT02830880","phase":"PHASE2","title":"FACBC Prostate Therapy Response","status":"COMPLETED","sponsor":"Emory University","startDate":"2016-07","conditions":"Prostate Cancer","enrollment":7},{"nctId":"NCT02578940","phase":"PHASE3","title":"Fluciclovine (18F) PET/CT in biochemicAL reCurrence Of Prostate caNcer","status":"COMPLETED","sponsor":"Blue Earth Diagnostics","startDate":"2015-11","conditions":"Cancer of the Prostate","enrollment":104},{"nctId":"NCT03409549","phase":"","title":"Multi-parametric MRI/Fluorine-18 Fluciclovine PET-CT in Glioblastoma","status":"UNKNOWN","sponsor":"The Leeds Teaching Hospitals NHS Trust","startDate":"2019-06-01","conditions":"Tumor, Brain","enrollment":12},{"nctId":"NCT03966443","phase":"","title":"Fluciclovine PET/CT in Multiple Myeloma Patients","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2019-03-01","conditions":"Myeloma, Multiple, PET-CT","enrollment":10},{"nctId":"NCT02680041","phase":"PHASE3","title":"18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment","status":"COMPLETED","sponsor":"Blue Earth Diagnostics","startDate":"2016-06-01","conditions":"Prostate Cancer","enrollment":221},{"nctId":"NCT01808222","phase":"PHASE2","title":"FACBC for Recurrent Prostate Cancer","status":"COMPLETED","sponsor":"David M. Schuster, MD","startDate":"2013-11","conditions":"Recurrent Prostate Cancer","enrollment":25},{"nctId":"NCT03036943","phase":"NA","title":"Fluciclovine (18F) Imaging of Breast Cancer","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2017-02-15","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT00562315","phase":"PHASE2","title":"FACBC PET/CT for Recurrent Prostate Cancer","status":"COMPLETED","sponsor":"David M. Schuster, MD","startDate":"2007-10","conditions":"Prostate Cancer","enrollment":128},{"nctId":"NCT00917865","phase":"PHASE2","title":"FACBC Positron Emission Tomography/Computed Tomography(PET/CT) Used in the Diagnosis of Primary Prostate Cancer","status":"TERMINATED","sponsor":"David M. Schuster, MD","startDate":"2008-04","conditions":"Prostate Cancers","enrollment":11}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":168,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["18F-FACBC","Axumin®"],"phase":"marketed","status":"active","brandName":"Fluciclovine PET/CT","genericName":"Fluciclovine PET/CT","companyName":"OHSU Knight Cancer Institute","companyId":"ohsu-knight-cancer-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fluciclovine is a fluorine-18 labeled amino acid analog that accumulates in cancer cells with high amino acid metabolism, enabling PET/CT imaging detection of malignant lesions. Used for PET imaging of suspected prostate cancer recurrence in men with elevated PSA, Detection and localization of various malignancies with high amino acid metabolism.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}